Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Research Reports

Microbiome Therapeutic Market Global Leading Companies Analysis, Revenue, Trends and Forecasts 2027

Published On :

 

 

The Microbiome Therapeutic Market shall be growing unabatedly in the future. The healthcare vertical is expected to go “personalized” in the next 10 years. Thus, genomics and genetics, along with the other biologic information, going personalized will help in early diagnosis of the disease and also how patients will respond to the treatments. Likewise, the healthcare vertical would be there to make greater strides in the forecast period.

According to the latest market report published by Persistence Market Research, titled ‘Microbiome Therapeutics Market Potential: Global Pipeline Analysis and Assessment 2018 – 2025’, the global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018–2025.

Persistence Market Research estimates that the global market for microbiome therapeutics is expected to be valued at US$ 10.1 Mn in 2018 and is expected to reach US$ 897.3 Mn by 2025 end. Need for reliable, precise and fast treatment options for certain diseases, such as C. difficile infection (CDI), phenylketonuria, hepatic encephalopathy and multidrug resistant urinary tract infection creates a huge potential for the growth of the microbiome therapeutics market. Breakthrough therapy designation and orphan drug approvals for microbiome therapeutics is expected to accelerate the launch of developmental drugs in the microbiome therapeutics market. A huge pipeline with over 120 candidates in different stages of development further creates the platform for potential growth of the microbiome therapeutics market.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/7990

Company Profiles:

  • Microbiome Therapeutics Inc.
  • SERES Therapeutics Inc.
  • LNC Therapeutics Inc.
  • Vedanta Biosciences Inc.
  • Enterome SA
  • Ferring B.V.
  • ViThera Pharmaceuticals Inc.
  • Second Genome Therapeutics
  • Rebiotix
  • Synlogic Inc.
  • 4D Pharma Plc.
  • Ritter Pharmaceuticals
  • AvidBiotics
  • Osel Inc.
  • OxThera AB
  • Evelo Biosciences
  • AOBiome LLC
  • Immuron Ltd.

Get A Customized Scope To Match Your Need Ask An Expert –  sales@persistencemarketresearch.com

Microbiome Therapeutic Market

More Than 120 Drugs Are in the Pipeline in the Global Microbiome Therapeutics Market

At present there are no marketed microbiome therapeutics in the global market; however, the first drug is expected to be launched in 2018. The global market is dominated by over 25 companies with more than 120 drugs in the pipeline at different stages of development. However, over 60% of these drugs are in the discovery or preclinical phase, where there is high uncertainty surrounding the success of these molecules to reach the clinical phase and being launched as a new drug molecule. Majority of the pipeline drugs are being developed for gastrointestinal disorders and contribute approximately 28.7% of the total pipeline products.

Research and development in the microbiome industry is prominently dependent on government funding and research grants. Formation of policies and provision of subsidy by various governments encourages research and development activities across various segments of the research including discovery and clinical research. Government initiatives in funding microbiome research is the preliminary factor driving revenue growth of global microbiome therapeutics market. For instance, the U.S. government had allocated US$ 1.6 Bn for microbiome R&D programs in 2016 & 2017.

Global Microbiome Therapeutics Market: Segmentation and Forecast

The market is segmented based on indication and region. On the basis of indication, the market has been segmented into type 2 diabetes, obesity, C. difficile infection and primary hyperoxyurea. C. difficile infection indication segment is expected to contribute the highest market share of over 34% by 2025 end. More number of product approvals for CDI is attributed to a high share of the C. difficile infection segment in the global market.

Human gut is home to over 100 Tn bacteria, containing thousands of different species. Long-term exposure to antibiotics causes dysbiosis in gut microbial composition, which leads to a variety of gastrointestinal disorders including CDI, ulcerative colitis, IBD, bacterial infection and even antibiotic associated diarrhea. Microbiome therapeutics however, present an excellent option for the treatment of CDI and other gastrointestinal disorders, as they are designed to naturally cure dysbiosis and bring the microbiome system back to normal functioning.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/7990

Global Microbiome Therapeutics Market: Regional Forecast

On the basis of region, the market has been segmented into the U.S., Europe, Japan and Rest of the World (RoW). U.S. is estimated to contribute the highest share of over 44% by 2025 end, due to early launch of microbiome therapeutics and high penetration compared to other markets. The market in Japan is expected to witness delayed growth due to the complex regulatory pathways for new biological drugs. The microbiome therapeutics market in the rest of the world is expected to show gradual acceptance of “bug medicine”, Canada being the most lucrative among the rest of the world countries.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

 

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts